NasdaqCM - Nasdaq Real Time Price USD

Vivos Therapeutics, Inc. (VVOS)

3.0000
+0.1600
+(5.63%)
At close: May 9 at 4:00:00 PM EDT
2.9800
-0.02
(-0.67%)
After hours: May 9 at 6:05:53 PM EDT

Research Analysis

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 3.7M
Earnings -2.83M

Q1'24

Q2'24

Q3'24

Q4'24

-2M
0
2M
4M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

5.50
5.85 Average
3.0000 Current
6.20 High

Earnings Estimate

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
No. of Analysts 2222
Avg. Estimate -0.4-0.35-1.27-0.83
Low Estimate -0.44-0.39-1.54-1.16
High Estimate -0.36-0.31-1-0.5
Year Ago EPS -1.63-0.6-2.22-1.27

Revenue Estimate

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
No. of Analysts 2222
Avg. Estimate 3.67M4.2M17.3M20.91M
Low Estimate 3.63M4.19M16.6M19.1M
High Estimate 3.7M4.2M18M22.73M
Year Ago Sales 3.42M4.05M15.03M17.3M
Sales Growth (year/est) 7.24%3.49%15.10%20.89%

Earnings History

Currency in USD 3/31/2024 6/30/2024 9/30/2024 12/31/2024
EPS Est. -1.16-1.05-0.7-0.43
EPS Actual -1.63-0.6-0.4-0.28
Difference -0.470.450.30.15
Surprise % -40.52%42.86%42.86%34.88%

EPS Trend

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
Current Estimate -0.4-0.35-1.27-0.83
7 Days Ago -0.36-0.31-1-0.5
30 Days Ago -0.41-0.35-1.430
60 Days Ago -0.41-0.35-1.430
90 Days Ago -0.41-0.35-1.430

EPS Revisions

Currency in USD Current Qtr. (Mar 2025)Next Qtr. (Jun 2025)Current Year (2025)Next Year (2026)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days 11----

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
VVOS 75.46%41.67%42.79%34.65%
S&P 500 13.21%3.09%8.02%13.76%

Upgrades & Downgrades

Maintains Ascendiant Capital: Buy to Buy 4/15/2025
Reiterates Ascendiant Capital: Buy to Buy 11/20/2024
Maintains Alliance Global Partners: Buy to Buy 11/19/2024
Maintains Ascendiant Capital: Buy to Buy 8/20/2024

Related Tickers